Please provide your email address to receive an email when new articles are posted on . Patients given aerosolized 4D-710 had elevated CFTR protein levels that went over normal levels. Over 12 months, ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...
A nanobody that stabilizes mutant CFTR from inside the cell, especially when combined with existing drugs, restores near-normal function in cystic fibrosis cells.
Sionna Therapeutics today announced the official launch of the company and the closing of a $111 million Series B financing. The round was led by OrbiMed with participation from funds advised by T.
Adding either of two new drugs — VX-659 or VX-445 — to the standard tezacaftor-ivacaftor combination improves both lung function and sweat chloride concentrations in most patients with cystic fibrosis ...
The drug is a small molecule with a novel mechanism of action, say David Bedwell, Ph.D., and Steven Rowe, M.D., MSPH, co-senior authors. Bedwell is professor and chair of the University of Alabama at ...
An experimental drug suggests that a 'path is clearly achievable' to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results